Orencia Uses
Links shared publicly online about this topic
Orencia wins expanded European licence | InPharm
inpharm.com — “Orencia wins expanded European licence | InPharm” View full resource at inpharm.com
Most Recently Shared on January 27, 2010 at 1:43 pm By:
Pharmafocus Health News and Pharma
Orencia wins expanded European licence. Bristol-Myers Squibb’s drug can now be used to treat juvenile arthritis. http://ow.ly/10VI5
NICE says no to BMS for second-line Orencia | InPharm
inpharm.com — “In final draft guidance NICE has not recommended the use of Bristol-Myers Squibb’s arthritis drug Orencia after other drugs have failed” View full resource at inpharm.com
Most Recently Shared on August 25, 2011 at 11:35 am By:
Pharmafocus Health News and Pharma
NICE says no to BMS for second-line Orencia http://ow.ly/6cnhz #nice #arthritis
New Data Show That Subcutaneous Injection Of An Investigational Formulation Of ORENCIA® Provided Similar Improvemnt Compared To Intraveous Therapy
medicalnewstoday.com — “(NYSE:BMY) announced that new Phase III clinical data show that a weekly subcutaneous injection of an investigational formulation of ORENCIA® (abatacept), following a single intravenous (I.V.)” View full resource at medicalnewstoday.com
Most Recently Shared on November 10, 2010 at 5:05 pm By:
MNT Arthritis News Health News
New Data Show That Subcutaneous Injection Of An Investigational Formulation Of ORENCIA® Provided Similar Improvemn... http://mnt.to/3Mm7
European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis - Drugs.com MedNews
drugs.com — “European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment o” View full resource at drugs.com
Most Recently Shared on July 8, 2010 at 10:40 am By:
European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after... http://bit.ly/annWwg
Orencia satisfaction and usage data | Monitoring more than 370 patients | Drug safety information | MediGuard
mediguard.org — “Orencia satisfaction and usage data | Monitoring more than 370 patients | Drug safety information | MediGuard” View full resource at mediguard.org
Most Recently Shared on May 10, 2011 at 8:17 pm By:
MediGuard.org Health Organization
94% of patients taking #orencia use it for Rheumatoid Arthritis ... http://tinyurl.com/4rkjozx
Reliable Sources: Orencia Cough Side Effect & Notions of e-Patients | Reality Check | Rheumatoid Arthritis Warrior
rawarrior.com — “If I cited a percentage of patients who get a cough from Orencia, then I--™d quote a source -- probably a clinical trial. However, if I merely say, as a...” View full resource at rawarrior.com
Most Recently Shared on March 22, 2011 at 10:00 am By:
Good morning! Today's blog is not just on side effects. It's also about whether what we say here is valid. One... http://fb.me/XWbq7GDJ
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
drugs.com — “Orencia (abatacept) is used for the treatment of rheumatoid arthritis. Information from Drugs.com includes Orencia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 2, 2011 at 12:27 am By:
FDA Approves Subcutaneous Formulation of Orencia - http://bit.ly/pjN8oc
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
drugs.com — “Orencia (abatacept) is used for the treatment of rheumatoid arthritis. Information from Drugs.com includes Orencia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 2, 2011 at 12:14 am By:
Drugs and Devices OW OW Health
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-A... http://bit.ly/qnjY9u #drug
Draft NICE Guidance Does Not Recommend Abatacept For Second-line Use In Rheumatoid Arthritis
medicalnewstoday.com — “The National Institute for Health and Clinical Excellence (NICE) has today (30 March 2011) opened a consultation on draft guidance which does not recommend abatacept (Orencia, Bristol-Myers Squibb” View full resource at medicalnewstoday.com
Most Recently Shared on March 31, 2011 at 2:56 am By:
Draft NICE Guidance Does Not Recommend Abatacept For Second-line Use In Rheumatoid Arthritis: The National Insti... http://bit.ly/dZu1fo
Is It Ethical To Use Placebo In Rheumatoid Arthritis Clinical Trials? - QualityPoint Technologies
qualitypointtech.net — “The results of this study, conducted in Germany, re-open the debate on whether it is ethical to conduct placebo-controlled studies where patients in the placebo-group are at a serious disadvantage compared to patients taking the new treatments. The study analysed current study designs, for new therapies such as abatacept (Orencia®), golimumab (Simponi®) or tocilizumab (Actemra®), and showed that patients in the placebo group experienced no change in medication, having to continue with their form” View full resource at qualitypointtech.net
Most Recently Shared on May 30, 2011 at 8:45 am By:
Is It Ethical To Use Placebo In Rheumatoid Arthritis Clinical Trials?: The results of this study, conducted in Ger... http://bit.ly/jzp1Bh
NICE nixes Bristol's arthritis med for NHS use - FiercePharma
fiercepharma.com — “Britain's healthcare cost watchdog NICE has recommended against using Bristol-Myers Squibb's (BMY.N) rheumatoid arthritis drug Orencia on the state health service as a second-line treatment. Report... Read more...” View full resource at fiercepharma.com
Most Recently Shared on March 30, 2011 at 3:31 pm By:
NICE nixes Bristol's arthritis med for NHS use. http://bit.ly/f46aa5
UK's cost agency rebuffs Bristol arthritis drug | Reuters
reuters.com — “LONDON (Reuters) - Britain's healthcare cost watchdog NICE has recommended against using Bristol-Myers Squibb's rheumatoid arthritis drug Orencia on the state health service as a second-line treatment.The” View full resource at reuters.com
Most Recently Shared on March 30, 2011 at 9:26 pm By:
UK's cost agency rebuffs Bristol arthritis drug http://reut.rs/hEmclt
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Pharmafocus
Monthly pharmaceutical, biotech & healthcare news publication for Europe. For pharma & biotech jobs follow @inpharmjobs. Twitter accounts run by @dominic_tyer
-
Pharmafocus
Monthly pharmaceutical, biotech & healthcare news publication for Europe. For pharma & biotech jobs follow @inpharmjobs. Twitter accounts run by @dominic_tyer
-
MNT Arthritis News
The latest arthritis / rheumatology news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
